Antigens Biomarkers Products & Reviews

Sino Biological has developed a series of ADC target protein products, including well-established targets such as HER-2, TROP-2, Nectin-4, EGFR, CD19, and BCMA, as well as emerging targets like EphA3, GFRA1, CLEC7A.

Sino Biological has developed a panel of recombinant Fc receptor products covering diverse isoforms and their mutants; these products can be utilized in various applications such as antibody screening, bioactivity assays during the CMC stage, consistency evaluation, and safety validation.

SARS-CoV-2 Nucleocapsid, clone 502 Monoclonal Antibody (matched pair with clone 504)

SARS-CoV-2 Nucleocapsid, clone 503 Monoclonal Antibody (matched pair with clone 504)

2019-nCoV Nucleocapsid Recombinant Antigen,full length (Ag-6)

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1057

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1058

SARS-CoV-2 Nucleocapsid, clone 504 Monoclonal Antibody (matched pair with clone 502 or 503)

SARS-CoV-2 Nucleocapsid, clone 2A1 Monoclonal Antibody (matched pair with clone 2C1)

SARS-CoV-2 Nucleocapsid, clone 2C1 Monoclonal Antibody (matched pair with clone 2A1)

SARS-CoV-2 Nucleocapsid, clone 4D8 Monoclonal Antibody (matched pair with clone 5B7)

SARS-CoV-2 Nucleocapsid, clone 5B7 Monoclonal Antibody (matched pair with clone 4D8)

SARS-CoV-2 Nucleocapsid,clone 7B3 Monoclonal Antibody (matched pair with clone 5D4)

SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 613

SARS-CoV-2 Spike (RBD, aa 331-524) Recombinant Antigen

SARS-CoV-2 Spike Protein S1 (aa 1-674) Recombinant Antigen

Sino Biological provides a wide range of influenza virus research reagents and technical services, supporting vaccine safety and immunogenicity assessment and vaccine protective efficacy evaluation.

Sino Biological provides comprehensive solutions for CAR-T cell therapy companies from CAR development, T cell activation, lentivirus packaging, CAR-T cell expansion to CAR-T cell quality control, fully supporting CAR-T research.

Sino Biological has developed a series of high-quality research reagents for dominant SARS-CoV-2 mutants, including recombinant antigens, detection antibodies, ELISA kits, pseudovirus, cDNAs, peptide pools, and receptor ACE2. These variant reagents have actively supported the basic research of SARS-CoV-2 and the development of vaccines, therapeutic antibodies, and diagnostic reagents.

Sino Biological provides comprehensive reagents and services for CAR-NK cell therapy development to support our customers from early target discovery to the preclinical phase of research and development.

Sino Biological has developed an extensive suite of recombinant complement proteins, covering C1s, C2, C3, C5, C7, Factor B, D, H, I and more, advancing the development of novel treatments targeting complement proteins.